{
  "pmcid": "9726788",
  "sha256": "7810995c305c5c227c7455f8ff085dfc8c138bc0eef40c170945631fbc6b8486",
  "timestamp_utc": "2025-11-09T23:01:53.394046+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.731140819964352,
    "reading_ease": 24.531417112299494,
    "word_count": 198
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Fluorescence-Guided Surgery and Photoimmunotherapy in Pancreatic Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this randomised controlled trial, 16 nude mice underwent surgical orthotopic implantation of the human pancreatic cancer cell line BxPC-3."
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Mice were randomised into FGS-only (n=8) and FGS + PIT (n=8) groups."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy of combining fluorescence-guided surgery (FGS) with photoimmunotherapy (PIT) using a fluorescent tumor-specific antibody."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the rate of metastatic recurrence, assessed four weeks post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applied."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Mice were randomised into FGS-only (n=8) and FGS + PIT (n=8) groups."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The metastatic recurrence rate was 100% in the FGS-only group and 25% in the FGS + PIT group (p=0.007)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 13,
    "max_score": 25
  }
}